IP Library › Granted Patent US 9,695,194
Granted Patent B2
US 9,695,194 · App. 15/113,750 · Granted Jul 4, 2017

Benzoxazinone derivatives for treatment of skin diseases

Inventors: Fredrik Wagberg (Lerum, SE); Goran Leonardsson (Kungsbacka, SE)
Assignee: SIXERA PHARMA AB
C07D498/04A61K31/536C07D265/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,695,194
App. No.
15/113,750
Granted
Jul 4, 2017
Kind
B2
Abstract

The present invention relates to methods and compositions for inhibiting the activity of skin proteases, especially human kallikrein 7 (KLK7), human kallikrein 5 (KLK5), and human kallikrein 14 (KLK14). More specifically, the invention relates to the use of substituted 3,1-benzoxazin-4-ones being selective inhibitors of human skin kallikreins for the treatment of skin diseases, more specifically for the treatment of inflammatory skins diseases, especially Netherton syndrome.

Claims (6)

1. A compound according to Formula I

wherein R is —S—CH 3 or —Cl, or a pharmaceutically acceptable salt thereof.

2. The compound 6-Ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one.

3. The compound 2-(2-Chlorophenyl)-6-ethoxy-7-methoxy-3,1-benzoxazin-4-one.

4. A method for treatment of a skin disease selected from Netherton syndrome, atopic dermatitis, contact dermatitis, eczema, psoriasis, acne, epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus comprising: administrating a therapeutically active amount of a compound according to claim 1 , to a subject in need of such treatment.

5. The method according to claim 4 , wherein the skin disease is Netherton syndrome.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTORNEY DOCKET NUMBER PREVIOUSLY RECORDED ON REEL 041395 FRAME 0720. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 8, 2017
From: WAGBERG, FREDRIK; LEONARDSSON, GORAN
To: SIXERA PHARMA AB
Reel/Frame 041916/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2017
From: WAGBERG, FREDRIK; LEONARDSSON, GORAN
To: SIXERA PHARMA AB
Reel/Frame 041395/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: WAGBERG, FREDERIK; LEONARDSSON, GORAN
To: SIXERA PHARMA, AB
Reel/Frame 040275/0099 →
Priority Claims (1)
SE 1430003 · Jan 23, 2014 · national
Continuity (1)
Related Publication 20170002021A1 · Jan 5, 2017